CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Regulation FD Disclosure
As previously disclosed in the press release issued on September 9, 2019 by CytoSorbents Corporation (the “Company”), Dr. Phillip P. Chan, the Company’s President and Chief Executive Officer, presented an overview of the Company at the H.C. Wainwright 21st Annual Global Investment Conference (the “Conference”), which was held on September 10, 2019. A copy of the presentation slides made at the Conference is attached hereto as Exhibit 99.1.
The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
|Exhibit No.||Exhibit Name|
|99.1||Presentation dated September 10, 2019|
Cytosorbents Corp Exhibit
EX-99.1 2 tv529496_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NASDAQ: CTSO HC Wainwright 21 st Global Investment Conference September 10,…
To view the full exhibit click
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.